INTRODUCTION
The biology of these three diseases and the pharmacology and clinical aspects of the so-called classical drugs used for their treatment have been adequately covered by excellent review articles. Consequently, the following discussion will emphasize some of the newer findings. Since coccidiosis is included in this review, the importance of this disease in domestic animals is demonstrated and will, therefore, be discussed.
AMEBIASIS
Amebiasis is an acute or chronic, enteric disease caused by the protozoan, Endamoeba histolytica. An excellent review article by Woolfe 1 covers its chemotherapy up to 1965. The following discussion will update this review with special emphasis given to chemical aspects.
Emetine and related compounds
The powdered root of Ipecacuanha has long been used for the treatment of amebic dysentery. Not until 1912 was it discovered that the antiamebic activity was primarily due to one of its major constituents, the alkaloid emetine. As a consequence of the establishment of the absolute configuration of natural or (-)-emetine (I) and its total synthesis, many derivatives Natural or (-)-Emetine became available for testing. Certain structure-activity relationships made during these studies have been summarized 1 . A few interesting pojnts are worthy of discussion. lmportance ofthe substitution at C-3. It has been reported that (±) -3-desethylemetine (II), prepared in various laboratories, has practically no activity in vivo 2 • Various racemic emetine derivatives with alkyl substituents at the 3-position, other than an ethyl group, prepared in our laboratories were also found tobe ofno interest. The configuration ofthese racemic compounds, however, was never established with certainty, and the conclusion that the The structures shown represent one of the two enantiomers. All compounds with the exception of (II) and (VI) are natural products.
alkyl group at the 3-po~ition must be ethyl is, therefore, not proven. The synthesis of racemic (II) with the correct relative configuration at the three asymmetric centres has recently been achieved at Burroughs Wellcome & Co. in England. It has been shown that this compound exerts modest antiamebic activity in vivo 3 • The finding, that the nature of the substituent at the 3-position is not as critical as had originally been supposed, is also supported by the fact that (±)-3-nordehydroemetine, a compound to be discussed later, is an active amebicide in vivo.
Other changes in the emetine molecule. Other changes, which are permissible without considerable loss of antiamebic activity, are variations in the substitution pattern in the aromatic portion of the isoquinoline moiety or replacement of the isoquinoline system by a carboline system. Cephaeline (111), a minor Ipecac alkaloid, tubulosine (IV) 4 and deoxytubulosine (V) 5 are amebicides 6 • It must be emphasized that the absolute configuration of these alkaloids is iden tical wi th tha t of natural emetine (I) . I t can also be anticipated that further changes, such as replacing one of the methoxy groups in ring A of emetine by a hydroxy group or replacing the tricyclic benzoquinolizidine moiety in emetine by an indoloquinolizidine moiety, could yield amebicides 7 • An interesting modification is the N-methyl-1',2'-secoemetine (VI) prepared from natural emetine in the Wyeth laboratories 8 • The N-acetyl derivative of this compound, tested unfortunately in vitro only, seemed tobe less active than emetine.
(±)-2,3-Dehydroemetine and (±)-3-nor-2,3-dehydroemetine
Another compound found during studies carried out in our laboratories; which warranted extensive investigation and which has now been successfully introduced into the market, is (±)-2,3-dehydroemetine (VII). The discovery of this compound was actually the result of an unsuccessful
The compounds discussed are racemates. The structures shown represent one of the two enantiomers.
attempt to reduce an unsaturated intermediate. When the final compound, which had an additional doub1e bond at the 2,3-position, was tested in vivo, it showed activity similar to emetine, but seemed to be less toxic. Extensive dinical investigations initiated by Herrero 9 and Blanclo and later extended world-widel, showed it to be equal to emetine as an amebicide. I t seemed, furthermore, to be better tolerated and faster excreted than emetine 11 • The nor-compound (VIII) prepared Iater was tolerated even better than (VII) but was also less active and, therefore, seemed to offer no advantage as an amebicide.
Mode of action of emetine and (±)-2,3-dehydroemetine
I t is of interest to note that Grollman, who studied the mechanism of action of emetine and related compounds, found that all the active compounds, including (VII), inhibit protein synthesis in certain mammalian and other cells 12 · 13 • This provides valuable information, wh.ich may account for the therapeutic and toxic properties of these substances. Since Grollman's results quite accurately parallel the in vivo screening results reported by various investigators, his in vitro test might be a valuable additional tool for the evaluation of compounds structurally related to emetine.
Technical synthesis of (-)-emetine and (±)-2,3-dehydroemetine
The total synthesis of (-)-emetine (I), identical with natural emetine, is now being performed on a large scale at Burroughs Wellcome & Co. in England. ( ±)-2,3-Dehydroemetine (VII) is presently being manufactured at Hoffmann-La Roche in Switzerland. The synthesis of any molecule as complex as emetine is a remarkable achievement. Emetine can now be made at any time and in any quantity. Furthermore, material produced by total synthesis has the advantage of being superior in quality, since the alkaloid from natural sources is always contaminated with impurities which are di:fficult to remove. Since (±)-2,3-dehydroemetine has two asymmetric centres less than (-)-emetine (I) and an optical resolution is not involved in its production, it is more readily available than synthetic (-) -emetine.
Clinical application of emetine and (±)-2,3-dehydroemetine
For treatment of severe acute amebic intestinal or extra-intestinal infections emetine (I), possibly replaceable by ( ±)-2,3-dehydroemetine (VII) which is more readily available, is still the drug of choice. I t is recommended that its use be followed by the administration of other drugs which are more effective against the subacute disease 1 .
Nitroheterocyclic compounds
Various investigators have detected high antiprotozoal act1v1ty among nitro-substituted heterocyclic compounds. Examples (given in Table 1 ) are the trichomonacide metronidazole (IX) 14 , the orally effective schistosomonacide niridazole (XI) 1 5, and the highly effective histomonastat dimetridazole (X)1 4 • Recent clinical studies have shown that both (IX)1 6 and (XI) 17 are also effective in the treatment of amebic dysentery and amebic liver abscesses. These findings have stimulated others working in this area. The Merck nitroimidazole (XII), for example, which has been reported to be a coccidiostat and a histomonastat 18 , is also an effective amebicide. The Roche compound (XIII, Ro 7-0207), a highly active amebicide is presently being prepared for extensive clinical studies. LD 50 and CD 50 values for these compounds in comparison with (±)-2,3-dehydroemetine dihydrochloride (VII. 2HC1), are given in Table Jl 9 • Extensive clinical studies with the above-mentioned nitroheterocycles will show whether these drugs approach the criteria set for a so-called ideal amebicide-one which, when given orally in completely non-toxic doses, would eradicate amoeba from the gut, Iumen, and tissues. 
COCCIDIOSIS
Coccidia are parasitic protozoa which infect vertebrates and invertebrates. Coccidiosis of chickens is practically universal and must be considered to be a serious economic threat to the poultry industry with its annual output of 2·8 billion broilers, 500 million layers and 120 million turkeys in the U.S.A. A variety of agents have been used for the prevention and treatment of coccidiosis in poultry. In the following discussion, those coccidiostats currently in use or now being developed will be mentioned. More detailed reviews may be found in the literature20.2I.
Prevention
Avian coccidiosis can be prevented by effective chemicals, called coccidiostats, administered via feed or drinking water. Sulphaquinoxaline (SQ) was one of the first known poultry coccidiostats, and its success stimulated the development of new and better-tolerated agents. The anticoccidial activity of sulpha drugs is antagonized by p-aminobenzoic acid, indicating that the sulpha drugs interfere with the p-aminobenzoic acid-folic acid metabolic sequence. 2,4-Diaminopyrimidines also interfere with this sequence, but at a different stage; thus, 2,4-diaminopyrimidines synergize or potentiate the anticoccidial activity ofsulpha drugs. This property is the basis for the development of combinations such as sulphadimethoxine and Ro 5-9754. This synergism of sulpha drugs by 2,4-diaminopyrimidines reduces the effective anticoccidial concentration ofthe pure sulpha drug. Data pertinent to several coccidiostats commercially available in the U .S.A. as well as others currently being developed are given in Table 3 . The data compiled therein are those released by the manufacturers, reported in the Iiterature or obtained in our own laboratory 22 • Only SQ, NICARB, co-BAN, Ro 2-2985, the combination ofsulphadimethoxine with Ro 5-9754, and STATYL are fully effective against five pathogenic species of Eimeria in chickens. In turkeys, only SQ, AMPROL, the combination of sulphadimethoxine with Ro 5-9754, and Ro 2-2985, evaluated thus far, appear to be fully effective against three pathogenic species of Eimeria. Table 3 also shows that the combination of sulphadimethoxine with Ro 5-9754, at the suggested coccidiostatic use Ievels, exerts in addition, high antibacterial activity against four major bacterial diseases in poultry, namely fowl cholera, infectious coryza, colibacillosis-CRD and salmonellosis.
Therapy
In spite of successful prophylactic coccidiosis control by extensive and continuous use of coccidiostats in the feed, sporadic outbreaks of coccidiosis do occur in flocks of poultry. Such outbreaks are best controlled by the administration of selected drugs in drinking water for short time intervals. This therapeutic concept of avian coccidiosis control introduced by Levine 2 3 led to the commercialization of several agents over the past two decades, most ofwhich are sulpha drugs. Renewed interest in the use of sulpha drugs has developed since the discovery of the so-called long-acting sulpha drugs. The anticoccidial and antibacterial activity of sulphadimethoxine, the active ingredient in the product, recently introduced under the trademark AGRIBON®, for therapeutic coccidiosis control is a result of this trend 24 · 25 . A good therapeutic response can be expected from AGRIBON®, since it is well tolerated, possesses good tissue retention, and has a relatively low excretion rate. Antibiotics. Several antibiotics isolated from cultures of unidentified strains of streptomyces several years ago 30 have shown broad-spectrum anticoccidial activity. The most interesting one, originally identified as X-537A and now termed Ro 2-2985, has excellent activity against all 5 important Eimeria species. It is characterized below. Another antibiotic (monensic acid, Eli Lilly & Co.) has also been shown tobe an effective coccidiostat. The structure of manensie acid has been elaborated by x-ray crystallographic analysis of its silver salt 3 \ and details on its biological properties have been reported 32 • Manensieacid and Ro 2-2985 aredifferent antibiotics but, based on accumulated data, they could be chemically related to each other.
Conclusions
The search for new coccidiostats will continue. One reason is the necessity of replacing drugs to which coccidia have developed resistance. Such compounds are more likely tobe found in chemieals which act by a different mechanism. Another reason is the desirability of having broad spectrum coccidiostats which have a combined effect against the various pathogenic Eimeria species, other protozoa and bacteria as weH. This is a major task because-even for an ideal drug-the cost will determine whether or not it will be marketable. In other words, in this field of endeavour, the biological spectrum is only one of the factors used to determine the utility of a drug.
MALARIA
Malaria, a disease caused by parasitic protozoa of the genus plasmodium, is still an unsolved international problem. Whereas the existence of this disease is dramatized by the current military operations in Southeast Asia, it is the emergence of drug-resistant strains of the malaria parasites which highlights the extreme gravity ofthe problem. Malaria and its chemotherapy have recently been reviewed in depth 33 -35 • This summary will, therefore, be restricted to some chemical aspects of some of the currently more important an timalarials.
Classical antimalarials
In the two decades between World Wars I and II, there was an uninterrupted intensive search for synthetic quinine substitutes. These efforts led to the discovery of several highly active compounds, mainly alkylaminoalkyl derivatives of aminoacridines such as quinacrine, and 4-and 8-aminoquinolines such as chloroquine and pamaquine. This important phase in the chemotherapy of malaria is weil documented and will not be discussed. Many of these compounds, particularly chloroquine, have, unfortunately, developed resistant strains of malarial parasites.
Biguanides and related compounds. The discovery of chloroguanide or paludrine is of special interest. In the body, chloroguanide is metabolized to a very active dihydrotriazine called cycloguanil. Cycloguanil is excreted too 180 rapidly in humans to be useful, but it forms an insoluble salt with pamoic acid, called CAMOLAR, which serves as a depot for cycloguanil3 5 . This repository form exhibits long-term prophylactic protection against certain susceptible malarial parasites, and its discovery, therefore, represents a significant theoretical advance in the chemotherapy of malaria. 
Sulphonamides and sulphones.

Cinchona alkaloids
Resistance ofmalaria parasites to all of the drugs mentioned, particularly to the 4-aminoquinolines, is steadily increasing. As a consequence, the use of the classical drug quinine is becoming increasingly more important. The correla6on of structure with activity of some major Cinchona alkaloids against avian malaria has been reported, but little is known of the validjty of these data with respect to human malaria. With the total synthesis of quinine by Woodward and Doering 39 , work on the chemistry of Cinchona alkaloids practically came to a standstill, and only a few significant papers appeared after 1950 40 • Therefore, we decided to reinvestigate the Cinchona alkaloids-quinine in particular, which is currently not readily available. The recent successful technical syntheses of the reserpine and emetine molecules, which are structurally as complex as quinine, encouraged us to attempt a technical synthesis of quinine and related compounds and in this way to participate in the search for better antimalarials.
Recent progress in the field of Cinchona alkaloids
It gives me great pleasure to report that a new synthesis ofnatural quinine has been achieved in our laboratories at Rochein Nutley (U .S.A). We have also improved the synthesis of (-)-dihydroquinine, an active antimalarial easily obtained from natural quinine by hydrogenation. This compound was first synthesized by Rabe 41 • We are at a stage where our synthesis of (-)-dihydroquinine can almost be considered tobe practical. Clearly the synthesis of (-)-dihydroquinine, which has an ethyl group in place of the vinyl group present in natural quinine, is much easier to achieve. Details of our chemical work will soon be reported by U skokovic, who was in charge of this programme from its inception 42 • The question concerning the absolute configuration of natural quinine and closely related alkaloids as it relates to their antimalarial activity has never been answered. In connection with our project it was important to know whether synthetic racemic quinine could be substituted for the natural alkaloid or whether an optical resolution would be necessary. Our most recent findings on th;s point are based only on a few experiments carried out by Brener 43 in mice infected with P. berghei. The results obtained by comparing synthetic (±)-dihydroquinine 44 with natural (-)-dihydroquinine, both as the sulphate salts, seem to indicate that the racemic mixture 
Conclusion
The development of new and better antimalarial drugs must continue. Fundamental work must be clone on the mechanism of drug action. Intensive studies concerning the development of resistance by malarial parasites and other aspects of the host-drug-parasite relationship rnust be pursued. Metabolie studies of important antimalarial drugs, such as quinine, are also necessary, because through knowledge gained frorn these studies the medicinal ehernist will be in a better position to achieve a possible breakthrough in the chemotherapy of malaria.
CLOSING REMARKS
With reference to each of the three topics-amebiasis, coccidiosis, and malaria-which I have discussed fron1 the chemist's point of view, it can be stated that, while considerable progress has been made, rnuch remains to be clone. In closing I wish to acknowledge the cooperation of Dr. A. Rachlin in preparing this lecture and the advice and support ofmany ofmy colleagues at Roche in Nutley (U.S.A.) and Basel (Switzerland) who are actively involved in studying several aspects of these three major protozoal diseases.
